SCHEMBL289711

SCHEMBL289711

NC(N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27559326 0.95
SCHEMBL27573942 0.95
SCHEMBL28006281 0.95
Hydrochloric Acid SCHEMBL27908669 0.91
Ethylene SCHEMBL8344090 0.91
Hydrochloric Acid SCHEMBL27891684 0.91
Hydrochloric Acid SCHEMBL27891688 0.91
Acetic Acid SCHEMBL1367670 0.88 FFAR3 (0.54)
Acetic Acid SCHEMBL530185 0.88 FFAR3 (0.54)
Acetic Acid SCHEMBL18813849 0.88 FFAR3 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120189368-A Moisturizing and wrinkle-removing eye cream and preparation method thereof 广西中绿医药科技有限公司 2025-06-24 CN claimed
US-20250041439-A1 ANTIBODY-DRUG CONJUGATES SPIREA LIMITED (GB) 2025-02-06 US claimed
WO-2024184315-A1 HBV CORE PROTEIN BINDING COMPOUNDS AND USES THEREOF JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) 2024-09-12 WO claimed
EP-4424699-A1 HBV CORE PROTEIN BINDING COMPOUNDS AND USES THEREOF Julius-Maximilians-Universität Würzburg (DE) 2024-09-04 EP claimed
EP-4404974-A1 ANTIBODY-DRUG CONJUGATES Spirea Limited (GB) 2024-07-31 EP claimed
EP-4313159-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY Feldan Bio Inc. (CA) 2024-02-07 EP claimed
WO-2024022465-A1 HUMAN AMYLIN POLYPEPTIDE DERIVATIVE AND USE THEREOF 杭州九源基因工程有限公司 2024-02-01 WO claimed
EP-4262879-A1 OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS Phi Pharma SA (CH) 2023-10-25 EP claimed
EP-4232590-A1 SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS Feldan Bio Inc. (CA) 2023-08-30 EP claimed
CN-116648266-A Oligomeric compounds that specifically bind to proteoglycans 菲药物股份有限公司 2023-08-25 CN claimed
EP-1646643-A2 C5A RECEPTOR ANTAGONISTS Jerini AG (DE) 2006-04-19 EP claimed
US-20050131208-A1 Method for producing a modified peptide DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-16 US claimed
CN-1612891-A Method for producing modified peptide DAIICHI SUNTORY PHARMA CO LTD (JP) 2005-05-04 CN claimed
EP-1135168-B1 PEPTIDES CARRYING SUBSTANCES ACROSS THE BLOOD BRAIN BARRIER SYNT EM SA (FR) 2005-04-20 EP claimed
WO-2005010030-A2 C5A RECEPTOR ANTAGONISTS JERINI AG (DE) 2005-02-03 WO claimed
EP-1493747-A1 PROCESS FOR PRODUCING MODIFIED PEPTIDE Daiichi Suntory Pharma Co., Ltd. (JP) 2005-01-05 EP claimed
US-20040248806-A1 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same SYNT:EM (FR) 2004-12-09 US claimed
EP-1135169-B1 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CANCER AGENT AND AT LEAST A PEPTIDE SYNT EM SA (FR) 2003-02-12 EP claimed
CN-1042931-A The preparation of rare earth addition and application WU JIAN (CN) 1990-06-13 CN claimed
CN-85107547-A Microchemiluminescent detection system 1987-04-15 CN claimed